# Closed-Loop Insulin Delivery Systems

> Closed-loop insulin systems for NEET-PG Medicine: CGM-pump-algorithm architecture, hybrid closed-loop, time-in-range targets and clinical trial evidence.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/closed-loop-systems
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Closed-Loop Insulin Delivery Systems", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/closed-loop-systems

## Direct answer

Sensor, pump and a control algorithm wired together form the hybrid closed-loop insulin delivery system — a continuous glucose monitor feeds interstitial glucose readings every few minutes to an algorithm embedded in the pump or a linked device, which automatically adjusts basal insulin (and, in newer systems, issues automatic correction boluses) while the user still announces meals and counts carbohydrates. The first hybrid closed loop was approved in 2016; contemporary systems (Medtronic 780G, Tandem Control-IQ, CamAPS FX, Omnipod 5, the dual-hormone-capable iLet bionic pancreas) have consistently improved time in the 70-180 mg/dL range and reduced hypoglycaemia versus sensor-augmented pump therapy in trials and real-world registries, with targets of time-in-range above 70 per cent now standard. Residual limitations define the "hybrid": meal announcements, infusion-set failures, site problems and algorithmic insulin action lag of 2-4 hours keep the human in the loop.

## What you must remember

- **Architecture trio:** continuous glucose sensor (wearable 10-15 day), insulin pump (or patch pump), and control algorithm — proportional-integral-derivative or model-predictive-control mathematics deciding basal rate every few minutes.
- **Levels of automation:** low-glucose suspend (stops on predicted hypo), predictive low-glucose suspend, hybrid closed-loop (automated basal plus auto-corrections; meals announced), and fully closed-loop systems (no meal announcement — still investigational in practice).
- **Landmarks:** Medtronic 670G was the first approved hybrid closed loop (2016); Control-IQ trials showed time-in-range gains of roughly 2-3 hours daily; the iLet bionic pancreas requires only body weight, not carb counting.
- **Targets that matter:** time in range 70-180 mg/dL above 70 per cent, time below 70 mg/dL under 4 per cent, below 54 under 1 per cent, glucose management indicator replacing informal HbA1c estimates — the metrics trials now report.
- **Evidence profile:** improved HbA1c (typically 0.3-0.5 percentage points), more time in range, and reduced hypoglycaemia — especially overnight, where automation excels; benefits persist in type 1 diabetes of all ages including pregnancy-optimised modes.
- **Failure modes to quote:** infusion-set occlusion and lipohypertrophy (the pump's Achilles heel — a failed cannula means NO insulin within hours in type 1), sensor inaccuracy during compression lows, post-meal excursions under unannounced meals, and vomiting illness outpacing algorithm assumptions.
- **Type 2 and hospital horizons:** closed loops improved glycaemia in type 2 diabetes trials (CamAPS-based studies), and automated insulin delivery research in hospital and post-operative care is expanding.
- **Indian context:** cost is the barrier — CGM-plus-pump therapy remains a metro, self-funded option for most; NACO-style national programmes do not cover it, but the physiology and targets are exam-relevant regardless.

## Living with the algorithm, day and night

Picture a 24-year-old with type 1 diabetes since childhood, HbA1c stuck at 8.4 per cent despite multiple daily injections and occasional severe nocturnal hypoglycaemia. She starts a hybrid closed loop: sensor applied to the abdomen, pump and tubing primed, system run in closed-loop mode overnight first, then full-time. The algorithm raises basal from midnight as CGM trends predict a 3 a.m. rise (dawn phenomenon) and throttles it back at 2 a.m. when the trend flattens; auto-corrections deliver small boluses when glucose crosses 180 mg/dL, catching the tail of every meal she under-announced. Three months later her time in range is 74 per cent, time below 70 is 2 per cent, and the nocturnal fear is gone. But the system has not repealed physics: when she develops gastroenteritis and her infusion site fails, the algorithm raises basal to chase a climbing glucose from an occluded cannula — ketoacidosis risk in a pump patient is minutes-to-hours, not days. Her sick-day rules remain: check ketones early with any unexpected high, change the set, and use pen insulin as backup. Automation manages the mean; the patient and her physician still manage the tails.

## Where students slip

The phrase "artificial pancreas" seduces candidates into "fully automatic, no patient input" — every deployed system is hybrid, with meal announcement and carbohydrate counting still expected; the exam tests that qualifier. The second miss is hypoglycaemia complacency: automation reduces but never abolishes severe hypoglycaemia, and driving rules still apply. Third, time-in-range metrics have displaced HbA1c-only reporting in trials; quoting 70 per cent time in range as the contemporary target earns the mark.

## Frequently asked questions

### What components make up a hybrid closed-loop insulin system?

A continuous glucose monitor, an insulin pump, and a control algorithm that adjusts basal insulin and automatic correction boluses continuously from sensor data.

### Why are current systems called "hybrid" closed loops?

Because users still announce meals and count carbohydrates; only basal insulin and correction dosing are automated, while fully autonomous no-announcement systems remain largely investigational.

### What glycaemic targets do closed-loop systems aim for?

Time in range 70-180 mg/dL above 70 per cent, time below 70 mg/dL under 4 per cent, and below 54 mg/dL under 1 per cent, alongside HbA1c improvement.

### What is the commonest failure mode of closed-loop therapy?

Infusion-set or cannula failure with lipohypertrophy — delivery stops abruptly in a type 1 patient, risking ketoacidosis within hours despite an intelligent algorithm.

### Do closed-loop systems help in type 2 diabetes?

Emerging trial evidence shows improved time in range in type 2 diabetes, including hospital studies, though access remains limited by cost and device availability.